---
title: "Keymed Biosciences Gains Approval for Stapokibart in Allergic Rhinitis Treatment"
date: "2025-02-07 16:39:49"
summary: "Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart PortfolioKeymed Biosciences, Inc. ( (HK:2162) )..."
categories:
  - "tipranks_announcements"
lang:
  - "en"
translations:
  - "en"
tags:
  - "tipranks_announcements"
menu: ""
thumbnail: "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1911898180-750x406.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

### Maximize Your Portfolio with Data Driven Insights:

* Leverage the power of [TipRanks' Smart Score](https://www.tipranks.com/screener/top-smart-score-stocks), a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
* Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with  [Your Smart Portfolio](https://www.tipranks.com/smart-portfolio/holdings)

Keymed Biosciences, Inc. ( [(HK:2162)](https://www.tipranks.com/stocks/hk:2162) ) just unveiled an update.

Keymed Biosciences, Inc. announced that China’s National Medical Products Administration has approved the supplemental New Drug Application for Stapokibart, a humanized antibody, for the treatment of seasonal allergic rhinitis. This approval is based on a successful phase III study showing Stapokibart’s efficacy and safety in controlling nasal and ocular symptoms. This development marks Stapokibart as the first domestically manufactured IL-4R α antibody drug granted marketing approval, which could enhance Keymed’s positioning in the biopharmaceutical market.

**More about Keymed Biosciences, Inc.**

Keymed Biosciences, Inc. is a company focused on the biotechnology industry, developing innovative therapeutic products. The company’s primary products include humanized antibodies targeting specific proteins involved in inflammatory processes, with a market focus on diseases such as atopic dermatitis and chronic rhinosinusitis.

**YTD Price Performance:** 2.43%

**Average Trading Volume:** 1,583,455

**Technical Sentiment Consensus Rating:** Buy

**Current Market Cap:** HK$8.28B

For a thorough assessment of 2162 stock, go to [TipRanks’ Stock Analysis page](https://www.tipranks.com/stocks/hk:2162/stock-analysis).

Trending Articles:
------------------

* [Amazon Bets Big on AI With $100B Planned Capex in 2025](https://www.tipranks.com/news/amazon-bets-big-on-ai-with-100b-planned-capex-in-2025)
* [Nikola Stock Plunges Over 24% on Probable Bankruptcy Filing News](https://www.tipranks.com/news/nikola-stock-plunges-over-24-on-probable-bankruptcy-filing-news)
* [‘The Nvidia Dream Is Fading,’ Says Bank of America About AMD Stock](https://www.tipranks.com/news/the-nvidia-dream-is-fading-says-bank-of-america-about-amd-stock)

[tipranks_announcements](https://www.tipranks.com/news/company-announcements/keymed-biosciences-gains-approval-for-stapokibart-in-allergic-rhinitis-treatment)
